Physician profile
Bachar Hamad
NPI 1780690040
$13,091.22
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,546 · 2020: $2,673 · 2021: $209 · 2022: $131 · 2023: $36.97 · 2024: $383 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,842.16 | 2019-2020 | |
| Boston Scientific Corporation | $319.08 | 2019-2025 | Exalt Model D, Extractor Pro Rx, Resolution 360 Ultra Clip |
| Abbvie INC. | $198.19 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $190.63 | 2021 | |
| Conmed Corporation | $134.46 | 2024 | Conmed Generators, Conmed Hemostasis |
| Ironwood Pharmaceuticals, INC | $115.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $63.34 | 2025 | Voquezna |
| Qol Medical, LLC | $54.09 | 2024 | Sucraid |
| Merck Sharp & Dohme LLC | $51.84 | 2019-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $39.35 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $38.76 | 2019-2020 | |
| Alfasigma USA, INC. | $28.46 | 2020 | |
| Janssen Biotech, INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.